EU Approves Wegovy Pill for Weight Loss

The European Commission (EC) has granted marketing authorization for Novo Nordisk’s Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity—making it the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states. This marks the fifth regulatory approval of Wegovy pill, after the U.S., UK, UAE and Bahrain.

“Today’s European Commission approval of Wegovy as a once-daily pill brings another important treatment option to people living with obesity,” said Mike Doustdar, president and CEO of Novo Nordisk.

The Wegovy pill approval is based on the OASIS clinical trial program, including OASIS 4, which evaluated once-daily oral semaglutide 25 mg in adults with obesity or overweight with at least one weight-related comorbidity. In the trial, oral semaglutide 25 mg demonstrated clinically meaningful and statistically significant weight loss of approximately 17% compared with 3% with placebo when used alongside lifestyle intervention. Around one in three individuals achieved 20% weight loss or more.

The European Commission (EC) also granted approval for Wegovy 7.2 mg injection in a single-dose pen for people living with obesity.

Novo Nordisk is committed to launching Wegovy pill in more countries in the second half of 2026.

Dive Deeper

Learn about GLP-1 Drugs and the Pharma Supply Chain.